NewAmsterdam Pharma Co N.V. Stock: price and insider trades · United States

NewAmsterdam Pharma Co N.V. is a listed company. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for NewAmsterdam Pharma Co N.V. logged 36 filings by 12 insiders.

On the market, 1 insider bought (1 purchase totalling €195k) while 6 insiders sold (14 sales totalling €6.6M). The totals do not cover 3 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €1.8M, sold by Kooij Louise Frederika and made public on 22 July 2026. On the buying side, the filings list 1 chief executive among the declarants.

For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 36 filings here. Since 2024, the database holds 13 purchases and 26 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 22.5 m USD and net income of -203.8 m USD.

The most recent open-market purchase was published on 15 September 2026, 32 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.